allyl-(2-chloro-ethyl)-sulfone | 149839-06-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 磺酰类
• 英文名称: allyl-(2-chloro-ethyl)-sulfone
• 英文别名: Allyl-(2-chlor-aethyl)-sulfon；3-(2-Chloroethylsulfonyl)prop-1-ene
• CAS: 149839-06-5
• 化学式: C₅H₉ClO₂S
• mdl: MFCD19234316
• 分子量: 168.644
• InChiKey: IBFCXSXDFYVYRH-UHFFFAOYSA-N

物化性质

• 沸点：
  297.6±33.0 °C(Predicted)
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  allyl-(2-chloro-ethyl)-sulfone 在 三乙胺 、 苯 作用下， 生成 3-ethenesulfonyl-propene
  参考文献：
  名称：

  Thermal Rearrangement of Allyl-type Sulfoxides, Sulfones and Sulfinates¹

  摘要：

  DOI：

  10.1021/ja01157a018
• 作为产物：
  描述：

  烯丙基2-氯乙基硫醚 在 双氧水 作用下， 生成 allyl-(2-chloro-ethyl)-sulfone
  参考文献：
  名称：

  Thermal Rearrangement of Allyl-type Sulfoxides, Sulfones and Sulfinates¹

  摘要：

  DOI：

  10.1021/ja01157a018

文献信息

• Vitamin-Receptor Binding Drug Delivery Conjugates
  申请人：Endocyte, Inc.

  公开号：US20160220694A1

  公开（公告）日：2016-08-04

  The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

  该发明描述了一种维生素受体结合药物传递共轭物及其制备方法。药物传递共轭物由维生素受体结合基团、双价连接剂（L）和药物组成。维生素受体结合基团包括维生素、维生素受体结合类似物及其衍生物，药物包括类似物及其衍生物。维生素受体结合基团与双价连接剂共价连接，药物或其类似物或衍生物与双价连接剂共价连接，其中双价连接剂（L）包括间隔连接剂、可释放连接剂和杂原子连接剂以及其组合。还描述了利用该药物传递共轭物消除病原细胞群的方法和药物组合物。
• Vitamin receptor binding drug delivery conjugates
  申请人：Endocyte, Inc.

  公开号：EP2517730A2

  公开（公告）日：2012-10-31

  The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety is a vitamin, or a vitamin receptor binding analog or a derivative thereof, and the drug includes analogs or derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker, where the bivalent linker (L) comprises one or more spacer linkers, releasable linkers, and heteroatom linkers. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

  本发明描述了一种与维生素受体结合的给药共轭物及其制剂。该给药共轭物由维生素受体结合分子、二价连接体（L）和药物组成。维生素受体结合分子是维生素或维生素受体结合类似物或其衍生物，药物包括其类似物或衍生物。维生素受体结合分子与二价连接体共价连接，药物或其类似物或衍生物与二价连接体共价连接，其中二价连接体（L）包括一个或多个间隔连接体、可释放连接体和杂原子连接体。此外，还描述了使用该给药共轭物消除致病细胞群的方法和药物组合物。
• FOLATE-VINBLASTINE CONJUGATE AS MEDICAMENT
  申请人：Endocyte, Inc.

  公开号：EP1592457B1

  公开（公告）日：2012-07-25
• VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES
  申请人：Vlahov Iontcho R.

  公开号：US20100004276A1

  公开（公告）日：2010-01-07

  The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.
• US7601332B2
  申请人：——

  公开号：US7601332B2

  公开（公告）日：2009-10-13